Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 28 (13), 115489
- https://doi.org/10.1016/j.bmc.2020.115489
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Orexin neurons suppress narcolepsy via 2 distinct efferent pathwaysJCI Insight, 2014
- The hypocretins/orexins: integrators of multiple physiological functionsBritish Journal of Pharmacology, 2013
- Discovery and Characterization of ACT‐335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective AntagonistChemMedChem, 2013
- Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleepBehavioural Brain Research, 2013
- Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor AlonePLOS ONE, 2012
- Differential Roles of Orexin Receptor-1 and -2 in the Regulation of Non-REM and REM SleepJournal of Neuroscience, 2011
- Orexin/Hypocretin: A Neuropeptide at the Interface of Sleep, Energy Homeostasis, and Reward SystemPharmacological Reviews, 2009
- Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null Mice: Molecular Genetic Dissection of Non-REM and REM Sleep Regulatory ProcessesNeuron, 2003
- Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding BehaviorCell, 1998
- The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activityProceedings of the National Academy of Sciences of the United States of America, 1998